Bicycle Therapeutics plc (NASDAQ:BCYC) reported Q2 EPS of ($0.90), $0.06 worse than the analyst estimate of ($0.84). Revenue for the quarter came in at $4.38 million versus the consensus estimate of $3.69 million.
Bicycle Therapeutics plc (NASDAQ:BCYC) reported Q2 EPS of ($0.90), $0.06 worse than the analyst estimate of ($0.84). Revenue for the quarter came in at $4.38 million versus the consensus estimate of $3.69 million.